Lyell Immunopharma Reports Unregistered Equity Sales
Ticker: LYEL · Form: 8-K · Filed: Jun 26, 2025 · CIK: 1806952
| Field | Detail |
|---|---|
| Company | Lyell Immunopharma, Inc. (LYEL) |
| Form Type | 8-K |
| Filed Date | Jun 26, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: equity-sale, unregistered-securities, financing
TL;DR
Lyell Immunopharma sold unregistered stock, potentially diluting existing shares.
AI Summary
On June 20, 2025, Lyell Immunopharma, Inc. filed an 8-K report detailing unregistered sales of equity securities. The filing does not specify the number of shares sold or the price per share, but it indicates a transaction occurred on or before June 20, 2025.
Why It Matters
This filing signals that Lyell Immunopharma has issued new equity without a prior public registration, which could impact existing shareholders through dilution or indicate a need for capital.
Risk Assessment
Risk Level: medium — Unregistered sales can sometimes indicate financial distress or a need for quick capital, and may lead to dilution for existing shareholders.
Key Players & Entities
- Lyell Immunopharma, Inc. (company) — Registrant
- June 20, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 201 Haskins Way South San Francisco, California 94080 (address) — Principal Executive Offices
FAQ
What type of equity securities were sold?
The filing states 'Unregistered Sales of Equity Securities' but does not specify the exact type of securities sold.
How many shares were sold in this unregistered offering?
The filing does not disclose the number of shares sold.
What was the price per share for these unregistered equity securities?
The filing does not provide information on the price per share.
Were these sales part of a private placement or another exemption from registration?
The filing indicates 'Unregistered Sales of Equity Securities' but does not detail the specific exemption from registration relied upon.
What is the purpose of these unregistered equity sales?
The filing does not state the purpose for the unregistered sales of equity securities.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 26, 2025 regarding Lyell Immunopharma, Inc. (LYEL).